Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma
NCT05493618Phase 2Withdrawn
- Sponsor
- Hackensack Meridian Health
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in multiple myeloma (MM), sponsored by Hackensack Meridian Health. Planned start Dec 2022; status: withdrawn.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05493618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493618.